Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases.
SARS-CoV-2
adult-onset Still’s disease
autoinflammatory diseases
cryopyrin-associated periodic syndrome
familial Mediterranean fever
systemic autoinflammatory diseases
vaccination
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
received:
13
10
2023
revised:
23
11
2023
accepted:
06
12
2023
medline:
23
12
2023
pubmed:
23
12
2023
entrez:
23
12
2023
Statut:
epublish
Résumé
Patients with systemic autoinflammatory diseases (sAIDs) are a section of the population at high risk of severe COVID-19 outcomes, but evidence on the efficacy of SARS-CoV-2 vaccination in this group of patients is scarce. To investigate the efficacy of SARS-CoV-2 vaccination in patients with sAIDs receiving interleukin-1 (IL-1) inhibition is important. Vaccination and infection responses from 100 sAID patients and 100 healthy controls (HCs) were analyzed. In total, 98% of patients were treated with IL-1 inhibitors at the time of vaccination (
Identifiants
pubmed: 38137656
pii: jcm12247587
doi: 10.3390/jcm12247587
pii:
doi:
Types de publication
Journal Article
Langues
eng